Résumé
Introduction : Prostate cancer incidence has a particularly high incidence in black male due to genetic predispositions. Men affected with prostate cancer are generally retired with limited financial resources. The aim of our study was to evaluate the cost of prostate cancer management in a tertiary hospital. Methodology: We conducted a descriptive study of the clinical and economic aspects of patients diagnosed with prostate cancer and managed at Hopital General Idrissa Pouye in 2018. We computed and aggregated the cost of diagnostic, therapeutic and follow. Results : Of our cohort of 105 patients mean age was 70 years with a predominance of the age group 60-69 years (48%). Mean hospital stay was 7 days. Sixty two percent of men were retired, 8% were farmers and 7% were traders. The cancer was metastatic in 81%, localized in 16%, land locally advanced in 3% of cases. Curative treatment was carried out in 16% of patients (8 radical prostatectomies, 8 radio-hormonal treatment) vs palliative treatment in 84% of patients. Complete Androgen Blockade (CAB) consisted of pulpectomy (63 patients) and LHRH analogues (14 patients). Cost of diagnostic procedures was XOF 28,497,000, cost of treatment was XOF 167,707,500 and the cost of follow-up was XOF 3,463,900 . The overall annual cost of prostate cancer management for the 105 patients was XOF 199,668,400 with an average annual cost of XOF 1,901,604 per patient. Conclusion: The cost of prostate cancer management was very high and was partly worsen by financial inaccessibility. Mortality and morbidity reduction requires the provision of larger advantages of Universal Medical Coverage and a better accessibility to drugs
